Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

209 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
VE-Cadherin modulates β-catenin/TCF-4 to enhance Vasculogenic Mimicry.
Delgado-Bellido D, Zamudio-Martínez E, Fernández-Cortés M, Herrera-Campos AB, Olmedo-Pelayo J, Perez CJ, Expósito J, de Álava E, Amaral AT, Valle FO, Diaz AG, Oliver FJ. Delgado-Bellido D, et al. Among authors: de alava e. Cell Death Dis. 2023 Feb 17;14(2):135. doi: 10.1038/s41419-023-05666-7. Cell Death Dis. 2023. PMID: 36797281 Free PMC article.
The clinical relevance of molecular genetics in soft tissue sarcomas.
Ordóñez JL, Osuna D, García-Domínguez DJ, Amaral AT, Otero-Motta AP, Mackintosh C, Sevillano MV, Barbado MV, Hernández T, de Alava E. Ordóñez JL, et al. Among authors: de alava e. Adv Anat Pathol. 2010 May;17(3):162-81. doi: 10.1097/PAP.0b013e3181d98cbf. Adv Anat Pathol. 2010. PMID: 20418671 Review.
Innovative therapies in Ewing Sarcoma.
Amaral AT, Ordóñez JL, Otero-Motta AP, García-Domínguez DJ, Sevillano MV, de Álava E. Amaral AT, et al. Among authors: de alava e. Adv Anat Pathol. 2014 Jan;21(1):44-62. doi: 10.1097/PAP.0000000000000003. Adv Anat Pathol. 2014. PMID: 24316910 Review.
Trabectedin efficacy in Ewing sarcoma is greatly increased by combination with anti-IGF signaling agents.
Amaral AT, Garofalo C, Frapolli R, Manara MC, Mancarella C, Uboldi S, Di Giandomenico S, Ordóñez JL, Sevillano V, Malaguarnera R, Picci P, Hassan AB, De Alava E, D'Incalci M, Scotlandi K. Amaral AT, et al. Among authors: de alava e. Clin Cancer Res. 2015 Mar 15;21(6):1373-82. doi: 10.1158/1078-0432.CCR-14-1688. Epub 2015 Jan 21. Clin Cancer Res. 2015. PMID: 25609059
The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin.
Ordóñez JL, Amaral AT, Carcaboso AM, Herrero-Martín D, del Carmen García-Macías M, Sevillano V, Alonso D, Pascual-Pasto G, San-Segundo L, Vila-Ubach M, Rodrigues T, Fraile S, Teodosio C, Mayo-Iscar A, Aracil M, Galmarini CM, Tirado OM, Mora J, de Álava E. Ordóñez JL, et al. Among authors: de alava e. Oncotarget. 2015 Aug 7;6(22):18875-90. doi: 10.18632/oncotarget.4303. Oncotarget. 2015. PMID: 26056084 Free PMC article.
Preclinical Efficacy of Endoglin-Targeting Antibody-Drug Conjugates for the Treatment of Ewing Sarcoma.
Puerto-Camacho P, Amaral AT, Lamhamedi-Cherradi SE, Menegaz BA, Castillo-Ecija H, Ordóñez JL, Domínguez S, Jordan-Perez C, Diaz-Martin J, Romero-Pérez L, Lopez-Alvarez M, Civantos-Jubera G, Robles-Frías MJ, Biscuola M, Ferrer C, Mora J, Cuglievan B, Schadler K, Seifert O, Kontermann R, Pfizenmaier K, Simón L, Fabre M, Carcaboso ÁM, Ludwig JA, de Álava E. Puerto-Camacho P, et al. Among authors: de alava e. Clin Cancer Res. 2019 Apr 1;25(7):2228-2240. doi: 10.1158/1078-0432.CCR-18-0936. Epub 2018 Nov 12. Clin Cancer Res. 2019. PMID: 30420447 Free PMC article.
Selective modulation by PARP-1 of HIF-1α-recruitment to chromatin during hypoxia is required for tumor adaptation to hypoxic conditions.
Martí JM, Garcia-Diaz A, Delgado-Bellido D, O'Valle F, González-Flores A, Carlevaris O, Rodríguez-Vargas JM, Amé JC, Dantzer F, King GL, Dziedzic K, Berra E, de Álava E, Amaral AT, Hammond EM, Oliver FJ. Martí JM, et al. Among authors: de alava e. Redox Biol. 2021 May;41:101885. doi: 10.1016/j.redox.2021.101885. Epub 2021 Feb 1. Redox Biol. 2021. PMID: 33581682 Free PMC article.
209 results